Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

EsbaTech brings in €32mm in Series B round; adds €14mm

Executive Summary

EsbaTech AG (develops antibody fragment therapeutics for Alzheimer's disease, cancer, and inflammation) raised €32mm ($41mm) in its Series B recapitalization financing round. New investors SV Life Sciences, Clarus Ventures, HBM BioVentures, and HBM BioCapital were joined by existing backers Novartis Venture Fund, BioMedinvest, and Venture Incubator (VI) Partners.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register